The Challenge for Development of Valuable Immuno-oncology Biomarkers
| Autor: | Deborah Collyar, Lyndsay Harris, Janice M. Mehnert, Larry Rubinstein, Arta M. Monjazeb, Johanna M.T. Beerthuijzen |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Cancer Research medicine.medical_treatment Oncology and Carcinogenesis Bioinformatics Article 03 medical and health sciences 0302 clinical medicine Lymphocytes Tumor-Infiltrating Neoplasms medicine Biomarkers Tumor Tumor Microenvironment Genetics Humans Lymphocytes Tumor-Infiltrating Oncology & Carcinogenesis Biomarker discovery Cancer Tumor microenvironment screening and diagnosis Tumor business.industry Clinical study design Human Genome Immunotherapy medicine.disease 4.1 Discovery and preclinical testing of markers and technologies Clinical trial Detection 030104 developmental biology Good Health and Well Being Oncology Annotated Tissue 030220 oncology & carcinogenesis Quality of Life Biomarker (medicine) business Biomarkers |
| Zdroj: | Clinical cancer research : an official journal of the American Association for Cancer Research, vol 23, iss 17 |
| Popis: | The development of immunotherapy is an important breakthrough for the treatment of cancer, with antitumor efficacy observed in a wide variety of tumors. To optimize immunotherapy use, approaches must be developed to identify which patients are likely to achieve benefit. To minimize therapeutic toxicities and costs, understanding the ideal choice and sequencing of the numerous immuno-oncology agents available for individual patients is thus critical, but fraught with challenges. The immune tumor microenvironment (TME) is a unique aspect of the response to immuno-oncology agents and measurement of single biomarkers does not adequately capture these complex interactions. Therefore, multiple potential biomarkers are likely needed. Current candidates in this area include PD-L1 expression, CD8+ tumor-infiltrating lymphocytes, tumor mutation load and neoantigen burden, immune-related gene signatures, and multiplex IHC assays that examine the pharmacodynamic and spatial interactions of the TME. The most fruitful investigations are likely to use several techniques to predict response and interrogate mechanisms of resistance. Immuno-oncology biomarker research must employ validated assays to ask focused research questions utilizing clinically annotated tissue collections and biomarker-focused clinical trial designs to investigate specific endpoints. Real-time input from patients and their advocates into biomarker discovery is necessary to ensure that the investigations pursued will improve both clinical outcomes and quality of life. We herein provide a framework of recommendations to guide the search for immuno-oncology biomarkers of value. Clin Cancer Res; 23(17); 4970–9. ©2017 AACR. See all articles in this CCR Focus section, “Clinical Trial Design Considerations in the Immuno-oncology Era.” |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|